Blueprint Medicines’ AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
— In the European Union, patients with indolent systemic mastocytosis now have an approved medicine that treats the primary driver of disease —
— Approval based on data from PIONEER trial, in which AYVAKYT achieved significant improvements across a broad range of symptoms with a safety profile comparable to placebo1 —
Related news for (BPMC)
- Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
- Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
- Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
- Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth